Diphenylethylene compounds and uses thereof
The present invention relates to Diphenylethylene Compounds and compositions comprising a Diphenylethylene Compound. The present invention also relates to methods for preventing or treating various diseases and disorders by administering to a subject in need thereof one or more Diphenylethylene Compounds. In particular, the invention relates to methods for preventing or treating cancer or an inflammatory disorder by administering to a subject in need thereof one or more Diphenylethylene Compounds. The present invention further relates to articles of manufacture and kits comprising one or more Diphenylethylene Compounds.
1. A compound of the formula:
or a pharmaceutically acceptable salt, solvate or hydrate thereof,
wherein:
one of R 1 and R 2 is —CN, and the other is —H, substituted or unsubstituted lower alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl;
each occurrence of R c and R d is independently —H, substituted or unsubstituted lower alkyl, or substituted or unsubstituted alkoxy;
R 3 is substituted or unsubstituted lower alkyl substituted or unsubstituted alkoxy or R 3 with R 4 , together form —O—(C(R 16 R 17 )) 2 —O —;
R 4 is substituted or unsubstituted lower alkyl or substituted or unsubstituted alkoxy;
R 5 is substituted or unsubstituted lower alkyl or substituted or unsubstituted alkoxy;
R 6 is —H, substituted or unsubstituted lower alkyl or substituted or unsubstituted alkoxy;
R 7 is —H, substituted or unsubstituted lower alkyl or substituted or unsubstituted alkoxy;
R 8 is —H, substituted or unsubstituted lower alkyl substituted or unsubstituted alkoxy, or R 8 with either R c or with R 7 , together form —O—(C(R 16 R 17 )) 2 —O—;
each occurrence of R 16 and R 17 is independently —H or halogen,
wherein either R 3 with R 4 , together form —O—(C(R 16 R 17 )) 2 —O— or R 8 with either R c or with R 7 , together form —O—(C(R 16 R 17 )) 2 —O—.
2. A compound of claim 1 , wherein R 3 , R 4 and R 5 are alkoxy.
3. A compound of claim 2 , wherein R 3 , R 4 and R 5 are methoxy.
4. A compound of claim 1 , wherein R 7 and R 8 are alkoxy.
5. A compound of claim 1 , wherein R 6 , R 7 and R 8 are alkoxy.
6. A compound of claim 1 , wherein R 1 is —H and R 2 is —CN.
7. A compound of claim 1 , wherein R 1 is —CN and R 2 is —H.
8. A compound of claim 1 , wherein the compound is the E isomer.
9. A compound of claim 1 , wherein the compound is the Z isomer.
10. A compound of the formula:
or a pharmaceutically acceptable salt, solvate or hydrate thereof,
wherein:
one of R 1 and R 2 is —CN, and the other is —H, substituted or unsubstituted lower alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl;
each occurrence of R a , R b , R c and R d is independently —H substituted or unsubstituted lower alkyl, or substituted or unsubstituted alkoxy;
R 3 is substituted or unsubstituted lower alkyl substituted or unsubstituted alkoxy, or R 3 with R a , together from —O—(C(R 16 R 17 )) 2 —O—;
R 4 is —H, substituted or unsubstituted lower alkyl or substituted or unsubstituted alkoxy;
R 5 is substituted or unsubstituted lower alkyl or substituted or unsubstituted alkoxy;
R 6 is substituted or unsubstituted lower alkyl or substituted or unsubstituted alkoxy;
R 7 is —H, substituted or unsubstituted lower alkyl or substituted or unsubstituted alkoxy;
R 8 is substituted or unsubstituted lower alkyl substituted or unsubstituted alkoxy, or R 8 with R c , together form —O—(C(R 16 R 17 )) 2 —O—;
each occurrence of R 16 and R 17 is independently —H or halogen,
wherein either R 3 with R a , together form —O—(C(R 16 R 17 )) 2 —O— or R 8 with R c , together form —O—(C(R 16 R 17 )) 2 —O—.
11. A compound of the formula:
or a pharmaceutically acceptable salt, solvate or hydrate thereof,
wherein:
one of R 1 and R 2 is —CN, and the other is —H, substituted or unsubstituted lower alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl;
each occurrence of R a , R b , R c and R d is independently —H, substituted or unsubstituted lower alkyl or substituted or unsubstituted alkoxy;
R 3 is —H, substituted or unsubstituted lower alkyl substituted or unsubstituted alkoxy, or R 3 with either R a or with R 4 , together form —O—(C(R 16 R 17 )) 2 —O—;
R 4 is —H, substituted or unsubstituted lower alkyl or substituted or unsubstituted alkoxy;
R 5 is —H, substituted or unsubstituted lower alkyl or substituted or unsubstituted alkoxy;
R 6 is —H, substituted or unsubstituted lower alkyl or substituted or unsubstituted alkoxy;
R 7 is —H, substituted or unsubstituted lower alkyl or substituted or unsubstituted alkoxy;
R 8 is —H, substituted or unsubstituted lower alkyl substituted or unsubstituted alkoxy, or R 8 with either R c or with R 7 , together form —O—(C(R 16 R 17 )) 2 —O—;
each occurrence of R 16 and R 17 is independently —H or halogen; and
with the proviso that if one of R 3 or R 5 is H, then the other is not substituted or unsubstituted lower alkyl or substituted or unsubstituted alkoxy and if one of R 6 or R 8 is H, then the other is not substituted or unsubstituted lower alkyl or substituted or unsubstituted alkoxy,
wherein either R 3 with either R a or with R 4 , together form —O—(C(R 16 R 17 )) 2 —O—or R 8 with either R c or with R 7 , together form —O—(C(R 16 R 17 )) 2 —O—.
12. A compound of the formula:
or a pharmaceutically acceptable salt, solvate or hydrate thereof,
wherein:
one of R 1 and R 2 is —CN, and the other is —H, substituted or unsubstituted lower alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl;
each occurrence of R a , R b , R c and R d is independently —H, substituted or unsubstituted lower alkyl or substituted or unsubstituted alkoxy;
R 3 is —H, substituted or unsubstituted lower alkyl substituted or unsubstituted alkoxy, or R 3 with either R a or with R 4 , together form —O—(C(R 16 R 17 )) 2 —O—;
R 4 is —H, substituted or unsubstituted lower alkyl or substituted or unsubstituted alkoxy;
R 5 is —H, substituted or unsubstituted lower alkyl or substituted or unsubstituted alkoxy;
R 6 is —H, substituted or unsubstituted lower alkyl or substituted or unsubstituted alkoxy;
R 7 is —H, substituted or unsubstituted lower alkyl, or substituted or unsubstituted alkoxy;
R 8 is —H, substituted or unsubstituted lower alkyl, substituted or unsubstituted alkoxy, or R 8 with either R c or with R 7 , together form —O—(C(R 16 R 17 )) 2 —O—;
each occurrence of R 16 and R 17 is independently —H or halogen; and
wherein at least one R a and R b and at least one of R c and R d is other than —H,
and wherein either R 3 with either R a or with R 4 , together form —O—(C(R 16 R 17 )) 2 —O— or R 8 with either R c or with R 7 , together form —O—(C(R 16 R 17 ) 2 —O—.
13. A compound of the formula:
or a pharmaceutically acceptable salt, solvate or hydrate thereof,
wherein:
one of R 1 and R 2 is —CN, and the other is —H, substituted or unsubstituted lower alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl;
each occurrence of R a , R b , R c and R d is independently —H, substituted or unsubstituted lower alkyl or substituted or unsubstituted alkoxy;
R 3 is —H, substituted or unsubstituted lower alkyl, substituted or unsubstituted alkoxy, or R 3 with either R a or with R 4 , together form —O—(C(R 16 R 17 )) 2 —O—;
R 4 is —H, substituted or unsubstituted lower alkyl or substituted or unsubstituted alkoxy;
R 5 is —H, substituted or unsubstituted lower alkyl or substituted or unsubstituted alkoxy;
R 6 is —H, substituted or unsubstituted lower alkyl or substituted or unsubstituted alkoxy;
R 7 is —H, substituted or unsubstituted lower alkyl or substituted or unsubstituted alkoxy;
R 8 is —H, substituted or unsubstituted lower alkyl, substituted or unsubstituted alkoxy, or R 8 with either R c or with R 7 , together form —O—(C(R 16 R 17 )) 2 —O—;
each occurrence of R 16 and R 17 is independently —H or halogen; and
wherein either R 3 with either R a or with R 4 , together form —O—(C(R 16 R 17 )) 2 —O— or R 8 with either R c or with R 7 , together form —O—(C(R 16 R 17 )) 2 —O—.
14. A compound of the formula:
or a pharmaceutically acceptable salt, solvate or hydrate thereof,
wherein:
one of R 1 and R 2 is —CN, and the other is substituted or unsubstituted lower alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl;
each occurrence of R a , R b , R c and R d is independently —H, substituted or unsubstituted lower alkyl or substituted or unsubstituted alkoxy;
R 3 is —H, substituted or unsubstituted lower alkyl, substituted or unsubstituted alkoxy, or R 3 with either R a or with R 4 , together form —O—(C(R 16 R 17 )) 2 —O—;
R 4 is —H, substituted or unsubstituted lower alkyl, or substituted or unsubstituted alkoxy;
R 5 is —H, substituted or unsubstituted lower alkyl or substituted or unsubstituted alkoxy;
R 6 is —H, substituted or unsubstituted lower alkyl or substituted or unsubstituted alkoxy;
R 7 is —H, substituted or unsubstituted lower alkyl or substituted or unsubstituted alkoxy;
R 8 is —H, substituted or unsubstituted lower alkyl, substituted or unsubstituted alkoxy, or R 8 with either R c or with R 7 , together form —O—(C(R 16 R 17 )) 2 —O—; and
each occurrence of R 16 and R 17 is independently —H or halogen,
wherein either R 3 with either R a or with R 4 , together form —O—(C(R 16 R 17 )) 2 —O—or R 8 with either R c or with R 7 , together form —O—(C(R 16 R 17 )) 2 —O—.
15. A compound or a pharmaceutically acceptable salt, hydrate or solvate thereof of the structure:
16. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
17. The pharmaceutical composition of claim 16 , wherein said composition is suitable for parenteral, transdermal, mucosal, nasal, buccal, rectal, sublingual, or oral administration to a subject.
18. A method for treating colon cancer comprising administering to a subject in need thereof an effective amount of the compound of claim 1 .
19. The method of claim 18 , wherein the compound is the E isomer.
20. The method of claim 18 , wherein the compound is the Z isomer.
21. The method of claim 18 , further comprising administering to said subject an effective amount of one or more anti-cancer agents.
22. The method of claim 21 , wherein at least one of the anti-cancer agents is paclitaxel, docetaxel, cisplatin, carboplatin, oxaliplatin, doxorubicin, gemcitabine, capecitabine, 5-fluorouracil, etoposide, cyclophosphamide, vincristine, vinblastine, topotecan or irinotecan.
23. The method of claim 21 , wherein at least one of the anti-cancer agents is an anti-angiogenic agent, a vascular targeting agent, an immunomodulatory agent or an anti-inflammatory agent.
24. The method of claim 18 , wherein said cancer is refractory to chemotherapy or radiation therapy.